journal article·2020-11-18Open access

Comparison of Methods for Surface Modification of Barium Titanate Nanoparticles for Aqueous Dispersibility: Toward Biomedical Utilization of Perovskite Oxides

Richard H. Huang, Nicholas B. Sobol, Ali Younes, Tanjeena Mamun, Jason S. Lewis, Rein V. Ulijn, Stephen O’Brien

ACS Applied Materials & Interfaces· Volume 12· Issue 46

Abstract

Colloidal perovskite barium titanate (BaTiO3, or BT) nanoparticles (NPs), conventionally used for applications in electronics, can also be considered for their potential as biocompatible computed tomography (CT) contrast agents. NPs of BT produced by traditional solid-state methods tend to have broad size distributions and poor dispersibility in aqueous media. Furthermore, uncoated BT NPs can be cytotoxic because of leaching of the heavy metal ion, Ba2+. Here, we present and compare three approaches for surface modification of BT NPs (8 nm) synthesized by the gel collection method to improve their aqueous stability and dispersibility. The first approach produced citrate-capped BT NPs that exhibited extremely high aqueous dispersibility (up to 50 mg/mL) and a small hydrodynamic size (11 nm). Although the high dispersibility was found to be pH-dependent, such aqueous stability sufficiently enabled a feasibility analysis of BT NPs as CT contrast agents. The second approach, a core/shell design, aimed to encapsulate BT nanoaggregates with a silica layer using a modified Stöber method. A cluster of 7–20 NPs coated with a thick layer (20–100 nm) of SiO2 was routinely observed, producing larger NPs in the 100–200 nm range. A third approach was developed using a reverse-microemulsion method to encapsulate a single BT core within a thin (10 nm) silica layer, with an overall particle size of 29 nm. The −OH groups on the silica layer readily enabled surface PEGylation, allowing the NPs to remain highly stable in saline solutions. We report that the silica-coated BT NPs in both methods exhibited a low level of Ba2+ leaching (≤3% of total barium in NPs) in phosphate-buffered saline for 48 h compared to the unmodified BT NPs (14.4%).
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Ferroelectric and Piezoelectric Materials · Quantum Dots Synthesis And Properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry and Biochemistry, The City College of New York, 1024 Marshak, 160 Convent Avenue, New York, New York 10031, United States

Advanced Science Research Center at The Graduate Center of the City University of New York, 85 Saint Nicholas Terrace, New York, New York 10031, United States

Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, 365 Fifth Avenue, New York, New York 10016, United States

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States

Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, New York 10065, United States

Department of Radiology and Pharmacology, Weill Cornell Medical College, New York, New York 10065, United States

Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States

Funding

Division of Chemistry · National Cancer Institute · Division of Human Resource Development · National Institute of Biomedical Imaging and Bioengineering · Division of Materials Research

References (71)

Show source-provided references
1. 10.1021/nl102959k10.1021/nl102959k ↗
2. 10.1016/J.CERAMINT.2010.08.04010.1016/J.CERAMINT.2010.08.040 ↗
3. 10.1039/c3ce27040h10.1039/c3ce27040h ↗
4. 10.1063/1.221876510.1063/1.2218765 ↗
5. 10.1021/cm00022a01910.1021/cm00022a019 ↗
6. 10.1021/am405627610.1021/am4056276 ↗
7. 10.1088/0957-4484/27/23/23200110.1088/0957-4484/27/23/232001 ↗
8. 10.1007/s11671-010-9607-010.1007/s11671-010-9607-0 ↗
9. 10.1038/nprot.2012.08710.1038/nprot.2012.087 ↗
10. 10.1021/acsanm.0c0001910.1021/acsanm.0c00019 ↗
11. 10.1016/j.actbio.2015.07.01010.1016/j.actbio.2015.07.010 ↗
12. 10.1111/j.1151-2916.2003.tb03307.x10.1111/j.1151-2916.2003.tb03307.x ↗
13. 10.1021/cm00022a01910.1021/cm00022a019 ↗
14. 10.1016/j.jeurceramsoc.2005.02.00310.1016/j.jeurceramsoc.2005.02.003 ↗
15. 10.1016/j.matlet.2013.02.10610.1016/j.matlet.2013.02.106 ↗
16. 10.1016/j.jallcom.2008.01.04510.1016/j.jallcom.2008.01.045 ↗
17. 10.1088/0957-4484/16/8/02610.1088/0957-4484/16/8/026 ↗
18. 10.1039/c2jm33373b10.1039/c2jm33373b ↗
19. 10.1021/ja011414a10.1021/ja011414a ↗
20. 10.1016/j.matlet.2006.06.00610.1016/j.matlet.2006.06.006 ↗
21. 10.1111/jace.1302310.1111/jace.13023 ↗
22. 10.1039/C5NR02351C10.1039/C5NR02351C ↗
23. 10.1038/nmat471810.1038/nmat4718 ↗
24. 10.1021/nn500299p10.1021/nn500299p ↗
25. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
26. Heitz F. · J. Radiol., Electrol., Med. Nucl. · 1974 · 55 · 430
27. 10.1016/s0955-2219(96)00116-110.1016/s0955-2219(96)00116-1 ↗
28. 10.1113/jphysiol.1978.sp01233810.1113/jphysiol.1978.sp012338 ↗
29. 10.1016/0021-9797(68)90272-510.1016/0021-9797(68)90272-5 ↗
30. 10.1021/la703440p10.1021/la703440p ↗
31. 10.1016/S0021-9797(03)00422-310.1016/S0021-9797(03)00422-3 ↗
32. 10.1016/j.jcis.2011.01.05810.1016/j.jcis.2011.01.058 ↗
33. 10.1039/c6tb01659f10.1039/c6tb01659f ↗
34. 10.1021/ja042886310.1021/ja0428863 ↗
35. 10.1021/cm302828d10.1021/cm302828d ↗
36. 10.1021/ac503544w10.1021/ac503544w ↗
37. 10.1021/cm202466810.1021/cm2024668 ↗
38. 10.1039/df951110005510.1039/df9511100055 ↗
39. 10.1021/jp992533410.1021/jp9925334 ↗
40. 10.1021/acs.jpcc.8b0966610.1021/acs.jpcc.8b09666 ↗
41. 10.1021/jp060974z10.1021/jp060974z ↗
42. 10.1016/0021-9797(92)90163-G10.1016/0021-9797(92)90163-G ↗
43. 10.1021/cm302828d10.1021/cm302828d ↗
44. 10.1021/cm051297910.1021/cm0512979 ↗
45. 10.1021/jp103872j10.1021/jp103872j ↗
46. 10.1021/nn800870r10.1021/nn800870r ↗
47. 10.1021/la202217710.1021/la2022177 ↗
48. 10.1016/j.jcis.2003.12.02510.1016/j.jcis.2003.12.025 ↗
49. 10.1111/j.1551-2916.2007.01787.x10.1111/j.1551-2916.2007.01787.x ↗
50. 10.1007/s11051-015-3321-x10.1007/s11051-015-3321-x ↗
51. 10.1039/c6nr00056h10.1039/c6nr00056h ↗
52. 10.1007/s11051-014-2376-410.1007/s11051-014-2376-4 ↗
53. 10.1088/0957-4484/25/48/48510110.1088/0957-4484/25/48/485101 ↗
54. 10.1002/jbm.a.3487910.1002/jbm.a.34879 ↗
55. 10.1016/S0025-5408(02)00820-610.1016/S0025-5408(02)00820-6 ↗
56. 10.1023/A:102230602490710.1023/A:1022306024907 ↗
57. 10.1016/S0955-2219(99)00241-110.1016/S0955-2219(99)00241-1 ↗
58. 10.1002/adfm.20110227210.1002/adfm.201102272 ↗
59. 10.1021/cm050884r10.1021/cm050884r ↗
60. Moffet, D.; Smith, C.; Stevens, Y.; Ingerman, L.; Swarts, S.; Chappell, L. Toxicological Profile for Barium and Barium Compounds; The Agency for Toxic Substances and Disease Registry, 2007; pp 1–231.
61. 10.1088/0031-9155/51/13/R0310.1088/0031-9155/51/13/R03 ↗
62. 10.1016/j.ymeth.2009.08.00710.1016/j.ymeth.2009.08.007 ↗
63. 10.3389/fphar.2015.0025610.3389/fphar.2015.00256 ↗
64. 10.1021/cr200358s10.1021/cr200358s ↗
65. 10.1021/acsami.0c0508810.1021/acsami.0c05088 ↗
66. 10.1002/adhm.20120002810.1002/adhm.201200028 ↗
67. 10.1016/S1076-6332(96)80333-310.1016/S1076-6332(96)80333-3 ↗
68. 10.7150/thno.3677710.7150/thno.36777 ↗
69. 10.1021/acs.molpharmaceut.9b0111110.1021/acs.molpharmaceut.9b01111 ↗
70. 10.1039/c1cs15233e10.1039/c1cs15233e ↗
71. 10.1016/j.jconrel.2016.01.02010.1016/j.jconrel.2016.01.020 ↗